Drug Profile
AZD 8329
Alternative Names: AZD8329Latest Information Update: 03 Feb 2012
Price :
$50
*
At a glance
- Originator AstraZeneca
- Class Antihypercalcaemics; Obesity therapies
- Mechanism of Action 11-beta-hydroxysteroid dehydrogenase type 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Obesity; Type 2 diabetes mellitus
Most Recent Events
- 31 Dec 2011 Discontinued - Phase-I for Obesity in Sweden (PO)
- 31 Dec 2011 Discontinued - Phase-I for Obesity in United Kingdom (PO)
- 31 Dec 2011 Discontinued - Phase-I for Type-2 diabetes mellitus in Sweden (PO)